GlassScriptPhysician profile
Samantha Willis
NPI 1568175941
$3,169.04
in general payments reported to CMS, 2019-2025
32 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $663 · 2024: $1,417 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.25 | 2023-2025 | |
| Lilly USA, LLC | $440.05 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $286.94 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Corium, LLC | $224.89 | 2023-2025 | Azstarys |
| Amgen INC. | $200.72 | 2023-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $199.24 | 2023-2025 | Trintellix, Eohilia |
| Regeneron Healthcare Solutions, INC. | $157.10 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $102.83 | 2023-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.44 | 2023-2024 | Jardiance, Tradjenta |
| Janssen Biotech, INC. | $73.07 | 2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $71.42 | 2025 | |
| Vanda Pharmaceuticals INC. | $59.01 | 2024-2025 | Fanapt |
| Celltrion USA INC. | $58.60 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $57.35 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $53.51 | 2025 | Bylvay |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.11 | 2023-2025 | Rexulti |
| Tolmar, INC. | $43.54 | 2024 | |
| Tris Pharma INC | $42.86 | 2024 | Dyanavel Xr |
| Lundbeck LLC | $41.85 | 2024-2025 | Vyepti |
| Pfizer INC. | $41.79 | 2024-2025 | |
| Exact Sciences Corporation | $33.97 | 2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $32.72 | 2023 | Wellbutrin, Aplenzin |
| Abbott Laboratories | $32.61 | 2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $30.31 | 2023 | Accrufer |
| Qol Medical, LLC | $27.50 | 2025 | Sucraid |
| Merz North America, INC. | $27.00 | 2024 | |
| Acadia Pharmaceuticals INC | $24.42 | 2025 | Daybue |
| Antares Pharma, INC. | $23.44 | 2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.10 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $18.54 | 2024 | |
| Axsome Therapeutics, INC. | $16.52 | 2024 | Auvelity |
| Currax Pharmaceuticals LLC | $14.34 | 2023 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.